- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04613687
Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM) (FREEDOM)
Evaluation of the Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of Venous or Mixed Predominantly Venous Leg Ulcers
Study Overview
Detailed Description
The compression bandage URGO BD001 is indicated for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous oedema and lymphedema justifying strong compression.
The pressure applied with the compression system URGO BD001 help to improve venous return and to reduce venous oedema. The expected clinical benefits from the compression system URGO BD001 in patient with a VLU are to increase healing rate and time to healing, and to improve patient quality of life.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Batot Géraldine, PhD
- Phone Number: +33 3 80 44 28 46
- Email: g.batot@fr.urgo.com
Study Contact Backup
- Name: Tacca Olivier, PhD
- Phone Number: +33 3 80 44 74 22
- Email: o.tacca@fr.urgo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient affected by VLU or mixed ulcer of predominantly venous origin (ankle brachial pressure index (ABPI) ≥ 0.8 and ≤ 1.3),
- Wound in granulation phase (granulation tissue ≥50%),
- Wound at least 3 cm away from any edge of another wound,
- VLU between 2 and 20 cm2 in surface area,
- VLU duration between 1 to 24 months.
Exclusion Criteria:
- Patient under guardianship or protection of vulnerable adult,
- Patient with known allergy to any components of the tested compression system,
- Patient with a severe illness that might lead to premature discontinuation of the trial before the end of treatment period,
- Patient with progressive neoplastic lesions treated by radiotherapy, chemotherapy, hormone therapy or immune suppressor,
- Patient with non-controlled systemic infection by a suitable antibiotic therapy,
- Patient who had a deep vein thrombosis within 3 months prior to the inclusion,
- Patient with a lymphedema due to lymphatic obstruction,
- Diabetic patient with advanced diagnosed microangiopathy,
- Bedridden patient, or those spending less than one hour per day on their feet,
- Wound covered partially or totally with necrotic tissue,
- Clinically infected wound,
- Wound requiring surgical treatment or for which a surgery is scheduled during the study period,
- Cancerous lesions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: URGOBD001
Compression bandage
|
Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative reduction in wound surface area (percent)
Time Frame: 6 weeks
|
Evolution between D0 and the 6 weeks treatment period with the URGO BD001 compression system: Relative reduction in wound surface area (%) = [(SW6 - SD0)/SD0] × 100 SD0: Wound surface area at D0 SW6: Wound surface area at Week 6
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete ulcer closure:
Time Frame: 6 weeks or last assessment
|
The percent (%) of patients with complete ulcer closure (100% re-epithelialization) after 6 weeks or at the latest treatment period
|
6 weeks or last assessment
|
Venous oedema
Time Frame: 6 weeks or last assessment
|
Oedema reduction from baseline (D0) and last assessment by measuring the limb circumference (in cm), using a tape:
|
6 weeks or last assessment
|
Patient quality of Life (EuroQoL 5D-5L)
Time Frame: 6 weeks or last assessment
|
EuroQoL 5D-5L between baseline and at last visit.
The questionnaire essentially consists of a descriptive system including 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and a visual analogue scale (EQ VAS) from "the worst health you can imagine" (0) to "the best health you can imagine" (100).
|
6 weeks or last assessment
|
Evolution of the periwound skin
Time Frame: 6 weeks or last assessment
|
Evolution of the peri-wound skin at each visit according to the following parameters:
|
6 weeks or last assessment
|
Safety analysis
Time Frame: 6 weeks or last assessment
|
Nature and number of adverse event related to the use of the testing compression system (serious/ non-serious)
|
6 weeks or last assessment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Senet Patricia, MD, Vascular dermatologist, APHP, Paris, France
- Principal Investigator: Dissemond Joachim, MD, Clinic for dermatology, Essen- Germany
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FI-19-09-BD001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on Compression bandage
-
Hospital Clinic of BarcelonaCompleted
-
University of AlcalaCompleted
-
Instituto Nacional de Cancer, BrazilRecruitingBreast Neoplasms | Lymphedema of Upper Arm | Breast Cancer Related Lymphedema | Lymphedema, SecondaryBrazil
-
Hvidovre University HospitalCompletedTotal Knee ArthroplastyDenmark
-
Massachusetts General HospitalNational Cancer Institute (NCI)TerminatedBreast Cancer | LymphedemaUnited States
-
TheraclionCompletedVaricose Ulcer | Veins Diseases | Vein, VaricoseAustria
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São PauloCompletedKnee OsteoarthritisBrazil
-
Gerencia de Atención Primaria, MadridFondo de Investigacion Sanitaria; Instituto de Salud Carlos IIICompleted
-
Abant Izzet Baysal UniversityCompletedBreast Cancer Lymphedema | Lymphedema of Upper Limb | Edema ArmTurkey
-
Rothman Institute OrthopaedicsCompleted